Please check your internet connection and try again.
# Aclidinium Bromide
## Overview
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) that functions as a bronchodilator. It acts by inhibiting M3 receptors on airway smooth muscle, leading to relaxation. It is structurally unrelated to "Walethmade" and is marketed under the brand name Tudorza Pressair.
## Primary Indications
Maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Not indicated for the relief of acute bronchospasm.
## Adult Dosing
The recommended dose is 400 mcg administered by oral inhalation twice daily (every 12 hours). Do not exceed 400 mcg per dose.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients. The condition (COPD) is generally not applicable to this population.
## Dose Adjustments
No dosage adjustment is required for patients with renal impairment or hepatic impairment.
## Contraindications
Hypersensitivity to aclidinium bromide, atropine, or derivatives. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction.
## Adverse Effects
Common: Headache, nasopharyngitis, cough, sinusitis.
Serious: Paradoxical bronchospasm (discontinue immediately), anticholinergic effects (worsening of urinary retention, constipation, or glaucoma).
## Key Drug Interactions
Avoid concomitant use with other anticholinergic medications (e.g., ipratropium, tiotropium) due to the risk of additive anticholinergic systemic effects.
## Monitoring
Monitor respiratory status, including FEV1, dyspnea scores, and frequency of rescue inhaler use. Assess for signs of urinary retention or ocular complications if pre-existing conditions are present.
## Clinical Pearls
- **Administration:** Ensure the patient is trained on the use of the Pressair multidose dry powder inhaler; the device includes a green-to-red control window to confirm successful inhalation.
- **Acute Use:** Emphasize that aclidinium is for maintenance only and does not replace short-acting beta-agonists (e.g., albuterol) for rescue therapy.
- **Anticholinergic Profile:** While systemic absorption is low, systemic anticholinergic side effects can occur, particularly in sensitive elderly populations.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and local protocols. Always verify current prescribing information, package inserts, and clinical guidelines before prescribing or administering any medication.
